Powder Characterisation for Additive Manufacturing: Freeman Technology Presents New Research
Tim Freeman, Managing Director, and Dr Xiaowei Fu, Product Specialist at Freeman Technology, will deliver four oral presentations relating to aspects of powder characterisation and critical powder handling issues at the 7th World Congress on Particle Technology (WCPT7) taking place from 19–22 May 2014 in Beijing, China.
Tim Freeman is an invited speaker at the Particle Design: Formulation and Processing session, where he will present ‘A QbD Approach to Continuous Tablet Manufacture’. This talk will focus on the use of powder characterisation to measure material properties that directly correlate with the quality attributes of a finished product to support the development of continuous processes.
In further presentations, Tim will cover the topics of ‘Understanding the mechanisms of particle interactions and powder flow’ and ‘Powder Flow Characterization — the need for an instrumental, multivariate approach’.
Dr Xiaowei Fu will speak about ‘Measurement and quantification of caking in powders’ — an issue widely encountered by powder processors in all industries.
In addition, new research on quantifying the effect of flow additives will also be presented in the poster session. Flow additives, lubricants or glidants are often used to improve processability of powders. Magnesium Stearate is used extensively as a lubricant in manufacturing pharmaceutical tablets and the poster will describe a study designed to gain greater understanding of the effects of this additive.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.